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Abstract: YKL-39 is a Glyco_18 domain containing chitinase-like protein which is currently recognized as a biomarker 
for the activation of chondrocytes and the progress of the osteoarthritis in human. YKL-39 was identiﬁ  ed as an abundantly 
secreted protein in primary culture of human articular chondrocytes. Two biological activities of YKL-39 might contribute 
to the disease progression. One is the induction of autoimmune response and second is the participation in tissue remodeling. 
Other mammalian chitinase-like proteins including chitotriosidase, SI-CLP, YKL-40 and YM1 are expressed by macrophages 
in various pathological conditions. In contrast, YKL-39 was never reported to be produced by macrophages. We used in 
vitro model of human monocyte-derived macrophage differentiation to analyse regulation of YKL-39 expression. Expression 
of YKL-39 was examined by real-time RT-PCR. CD14+ MACS sorted human monocytes differentiated for 6 days under 
different stimulations including IFNγ, IL-4, dexamethasone and TGF-β. We found that both IL-4 and TGF-β have weak 
stimulatory effect on YKL-39 expression in all donors tested (3.2 ± 1.7 fold, p = 0.006 and 6.3 ± 3.1 fold, p = 0.014 
respectively). However the combination of IL-4 and TGF-β had strong stimulatory effect on the expression of YKL-39 in 
all analysed individual macrophage cultures (34 ± 36 fold, p = 0.05). IFN-γ did not show statistically signiﬁ  cant effect of 
YKL-39 mRNA expression. Presence of dexamethasone almost completely abolished the stimulatory effects of IL-4 and 
TGF-β. In summary, we show here for the ﬁ  rst time, that human cells of monocyte origin are able to produce YKL-39. 
Maturation of monocyte derived macrophages in the presence of Th2 cytokine IL-4 and TGF-β leads to the strong activation 
of YKL-39 expression. Thus elevated levels of YKL-39 observed during chronic inﬂ  ammations can not be attributed solely 
to the activity of chondrocytes. In perspective, YKL-39 might serve as a useful biomarker to detect macrophage-speciﬁ  c 
response in pathologies like tumour, atherosclerosis and Alzheimer disease.
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Introduction
YKL-39 (homo sapiens chitinase-like 2, CHI3L2) is currently recognized as a biochemical marker 
for the activation of chondrocytes and the progress of the osteoarthritis in human (Knorr et al. 2003). 
YKL-39 is secreted human chitinase-like protein which contains Glyco_18 domain with no catalytic 
activity but with putative lectin properties (Funkhouser et al. 2007; Kzhyshkowska et al. 2007). 
YKL-39 was originally identiﬁ  ed as an abundantly secreted protein in primary culture of human 
articular chondrocytes (Hu et al. 1996). In contrast to its closest homologue YKL-40, YKL-39 is not 
a glycoprotein. Although the number of aminoacids was slightly bigger in YKL-39, apparent higher 
MW of YKL-40 is due to the presence of carbohydrate (Hu et al. 1996). YKL-39 accounted for 4% 
and YKL-40 for 33% of the secreted protein in chondrocyte-conditioned medium. Despite the high 
homology on the protein level (more than 50%), the radioimmunoassay developed for the detection 
of YKL-40 in serum and in tissues, was shown to detect exclusively YKL-40 but not YKL-39 (Hu 
et al. 1996).
Comparison of the expression of YKL-39 and YKL-40 in osteoarthritic cartilage revealed, that 
YKL-39 mRNA is signiﬁ  cantly up-regulated in cartilage of patients with osteoarthritis (OA) versus 
normal subjects, while no signiﬁ  cant up-regulation was detected for YKL-40 mRNA in OA cartilage 
(Steck et al. 2002). Study of Knorr et al. showed that normal human chondrocytes express mRNA for 
both YKL-39 and YKL-40. However while the expression of YKL-39 was upregulated both in early 40
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degenerative and late stage osteoarthritis, the 
expression of YKL-40 was downregulated during 
the progression of osteoarthritis (Knorr et al. 2003). 
Proteomic analysis identiﬁ  ed YKL-39, but not 
YKL-40 to be secreted by human osteoarthritic 
cartilage in culture (De Ceuninck et al. 2005).
The closest homologue of YKL-39, YKL-40 
has multiple biological activities, including a 
growth-promoting effect on human synovial cells, 
skin and fetal lung ﬁ  broblasts as well as immuno-
modulatory effects on monocytes and T-cells, 
while examination of the biological effects of 
puriﬁ  ed YKL-39 remains to be done (reviewed in 
Kzhyshkowska et al. 2007). However two physi-
ological activities of YKL-39 might contribute to 
the disease progression. First one is the induction 
of autoimmune response (Du et al. 2005; Sekine 
et al. 2001; Tsuruha et al. 2002), and second is 
predicated participation in tissue remodeling.
Several mammalian Glyco_18 domain contain-
ing proteins are expressed by macrophages in 
various physiological situations (Kzhyshkowska 
et al. 2006; Kzhyshkowska et al. 2007). Thus, 
enzymatically active chitotriosidase is expressed 
by mature monocyte derived macrophages, lung 
macrophages and Gaucher cells (Boot et al. 1999; 
Di Rosa et al. 2005; Malaguarnera et al. 2005; 
Renkema et al. 1995; van Eijk et al. 2005). Gaucher 
cells are abnormal lipid-laden macrophages formed 
in tissues of Gaucher Disease patients. Gaucher 
cells can be classiﬁ  ed as a variation of alternatively 
activated macrophages (Boven et al. 2004). Thus 
chitotriosidase is used as a highly speciﬁ  c serum 
biomarker for lysosomal storage disorder (Aerts 
et al. 2005). Macrophages seem to be the source 
of secreted YKL-40, which serum levels are ele-
vated in numerous tumours, chronic and acute 
inﬂ  ammations and during ﬁ  brosis progression. 
Catalytically inactive SI-CLP (stabilin-1 interact-
ing chitinase-like proteins) and murine YM1/2 are 
expressed by macrophages in Th2-environment 
(Hogenesch et al. 2006; Kzhyshkowska et al. 2006; 
Raes et al. 2002; Webb et al. 2001).
In contrast to other mammalian Glyco_18 
domain containing proteins, YKL-39 production 
is clearly documented only for chondrocytes and 
synoviocytes (Hu et al. 1996). Recently we per-
formed comparative quantitative analysis using 
real-time RT-PCR and demonstrated that YKL-40 
was strongly upregulated by IFNγ, while YKL-39 
mRNA was expressed on a very low level in mac-
rophages differentiated in the presence of IFNγ, 
IL-4 or dexamethasone (Kzhyshkowska et al. 
2006). To our knowledge there is only one report 
suggesting that YKL-39 can be expressed by cells 
of monocyte origin. Messenger RNAs for both 
YKL-39 and YKL-40 were strongly upregulated 
in the brain of patients with Alzheimer disease, and 
this fact was attributed to the alternative activation 
of microglial macrophages during the course of 
the disease (Colton et al. 2006). However speciﬁ  c 
stimuli responsible for the induction of YKL-39 
were never demonstrated.
Here we present the evidence, that macrophages 
are able to produce YKL-39 in response to TGF-β 
stimulation. Analysis of human primary monocyte-
derived macrophages revealed, that their differen-
tiation in the presence of TGF-β and Th2 cytokine 
IL-4 leads to strong statistically signiﬁ  cant activa-
tion of YKL-39 mRNA. Single stimulations with 
IL-4 alone and TGF-β alone had only slight 
stimulatory effect, while dexamethasone inhibited 
expression of YKL-39 mRNA. These data suggest, 
that elevated levels of YKL-39 observed during 
chronic inﬂ  ammation can be assigned not only to 
the activation of synovial cells, and macrophages 
can contribute to the YKL-39 production if IL-4 
and TGF-β are present concomitantly. Elevated 
level of YKL-39 can be also expected in patholo-
gies like tumour, neurodegenerative diseases and 
atherosclerosis.
Materials and Methods
Monocyte isolation and cultivation 
of macrophages
The isolation and cultivation of human monocytes/
macrophages was done as described (Gratchev 
et al. 2004; Gratchev et al. 2005; Gratchev et al. 
2006). The cells were puriﬁ  ed from individual 
buffy coats. Buffy coats were diluted with Ca
2+- 
and Mg
2+- free phosphate-buffered saline (PBS) 
(Biochrom) at a ratio 1:1. A total of 35 ml of diluted 
buffy coats were layered on top of 15 ml Ficoll-
Paque (Biochrom, Berlin, Germany) in a 50-ml 
Leucosep tube (Greiner, Fickenhausen, Germany). 
After 30 min of centrifugation in a swing out rotor 
(Beckman Coulter, Fullerton, CA, U.S.A.) at 650 × g, 
peripheral blood mononuclear cells (PBMC) were 
collected from the Ficoll serum interphase. PBMCs 
were washed two times with PBS (Biochrom). The 
Percoll gradient was preformed by centrifugation 
of freshly prepared Percoll (13.5 ml Percoll 41
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(Pharmacia, Freiburg, Germany), 1.5 ml 10 × 
Earle’s Minimal Essential Medium (MEM), 15 ml 
Spinner’s medium) at 12000 × g for 10 min at 20 °C 
without breaks in a F34-6-38 rotor (Eppendorf, 
Hamburg, Germany). Five to 8 × 10
8 PBMCs were 
layered on top of the Percoll gradient and centri-
fuged at 650xg for 30 min at 20 °C without breaks. 
The upper layer, containing 60%–80% monocytes 
was collected and washed three times with PBS. 
The cell population obtained after Percoll gradient 
centrifugation was subjected to CD14+ magnetic 
cell sorting using monocyte isolation kit (Miltenyi 
Biotech, Bergisch Gladbach, Germany), resulting 
in 92-98% monocyte purity, controlled by ﬂ  ow 
cytometry. Macrophages were cultured at 1 × 10
6 
cell/mL in X-vivo 10 serum free medium (Cam-
brex, Verviers, Belgium), supplemented with 
cytokines and/or dexamethasone as indicated, for 
6 days.
Following stimulators were used: human inter-
feron (IFN)γ, from TEBU Peprotech (Frankfurt am 
Main, Germany), at a concentration of 1000 U/ml; 
IL-4 from TEBU Peprotech, at a concentration of 
10 ng/ml; dexamethasone (Sigma) at a concentra-
tion of 1 × 10
−7 M; TGF-β1 from Tebu Peprotch 
at a concentration of 10 ng/ml.
Isolation of RNA and synthesis 
of cDNA
For RNA isolation, the cells were lysed directly in 
the plastic Petri dishes and the RNA was isolated 
using RNeasy Mini kit (Qiagen, Hilden, Germany) 
according to the recommendations of the manu-
facturer. Total RNA (2 μg) was treated with 2U 
RNase free DNase (Ambion, Austin, TX, USA) 
and used for Reverse Transcription (RT) with 
Superscript III reverse transcriptase (Invitrogen, 
Karlsruhe, Germany) using oligo dT primers 
according to the recommendations of the manu-
facturer. Obtained cDNA was diluted 1:10 with 
DDH2O and 1 μl was used for PCR reaction.
Real-time PCR analysis
Real-time RT-PCR analysis of YKL-39 was per-
formed using Hs00187790_m1 TaqMan
® assay 
(Applied Biosystems, Darmstadt, Germany). For 
normalization a house keeping index (HKI) was 
generated basing on the analysis of the expression 
of GAPD, ACTB and HPRT1 (Vandesompele et al. 
2002). For the analysis of the expression of ACTB 
and HPRT1 ready TaqMan probes Hs03023880_g1 
and Hs99999909_m1 respectively were used 
(Applied Biosystems). The assay for GAPDH 
consisted of following oligonucleotides: sense 
primer 5′- CATCCATGACAACTTTGGTATCGT 
used at 900 nM, antisense primer 5′-CAGTCTTCT-
GGGTGGCAGTGA used at 300 nM and TaqMan
® 
probe JOE-AAGGACTCATGACCACAGTC-
CATGCC-BHQ1 used at 200 nM. Oligonucle-
otides were synthesized by MWG-Biotech 
(Ebersberg, Germany). The experiments were 
performed on ABI PRISM
® 7000 sequence detec-
tion system (Applied Biosystems) using standard 
conditions. Relative quantiﬁ  cation of the expres-
sion levels of analysed gene was performed using 
ΔΔCt method. For standard curve generation 5 
serial dilution points of a PCR product, containing 
target sequence ranging from 10
3 to 10
8 copies 
were used. The efﬁ  ciencies of all reactions were 
above 95%.
Statistics
Statistical analysis of real-time RT-PCR results 
was performed using ANOVA function of Excel 
program of Microsoft
® ofﬁ  ce XP.
Results and Discussion
Several Glyco_18 domain containing proteins, 
which comprise family of mammalian chitinases 
and chitinase-like proteins, were found to be abun-
dantly expressed by macrophages both in human 
and in rodents. However, chitinase-like proteins 
YKL-39 was only found to be expressed by syno-
vial ﬁ  broblasts during osteoarthritis (OA) (Knorr 
et al. 2003; Steck et al. 2002). During arthritis, 
monocytes and macrophages are attracted to the 
sites of inﬂ  ammation due to high levels of galectin 
3 (Karouzakis et al. 2006). Further macrophages 
are exposed to high levels of TGF-β. We addressed 
the question, whether TGF-β is able to induced 
YKL-39 expression in monocyte-derived human 
macrophages. Monocytes were isolated from buffy 
coats by sequential gradient centrifugation and 
enriched using CD14 MACS sorting to achieve 
over 95% of purity. Immediately after isolation 
monocytes were stimulated by single cytokines or 
their combinations. Following stimulations were 
used: IL-4; TGF-β; IL-4+TGF-β; IL-4+dexameth-
asone; IL-4+dexamethasone+TGF-β; 
dexamethasone+TGF-β; IFNγ; IFNγ+TGF-β. After 
six days of differentiation in culture, cells were 
harvested and RNA was used for the quantiﬁ  cation 42
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of YKL-39 expression level. Non-stimulated 
monocyte-derived macrophages cultivated for 6 
days were used as a control. Since there are no 
commercially available anti-YKL-39 antibodies 
we evaluated YKL-39 expression regulation on the 
mRNA level.
Real-time PCR analysis revealed, that TGF-β 
alone has stimulatory effect of 4.1 to 12.7 times in 
four out of ﬁ  ve donors tested (Fig. 1A, Table 1). 
This effect was statistically signiﬁ  cant with p = 0.014 
(Fig. 1B). TGF-β is potent regulatory cytokine with 
diverse activities. Well established function of TGF-β 
in immune system is to maintain tolerance by 
controlling proliferation, differentiation, activation 
and survival of various immune cells (Li et al. 2006). 
TGF-β is produced by numerous cell types including 
T-and B-lymphocytes, NK cells, DCs, macrophages, 
mast cells, and granulocytes. In particular granulocytes 
may inﬂ  uence synovial effusion by production of 
TGF-β1. Potent source of high levels of TGF-β are 
tumour cells. During cancer progression tumour 
cells frequently lose the growth-inhibitory responses 
to TGF-β and instead beneﬁ  t from high TGF-β 
levels (Bierie et al. 2006). In particular beneﬁ  cial 
effects of high TGF-β levels can be due to 
modulation of phenotype of tumour associated 
macrophages (TAM) which help tumour to establish 
immunologically tolerogenic environment. Our data 
suggest that YKL-39 can be expected to be secreted 
by TAMs. Further examination for speciﬁ  c tumours 
is needed to consider YKL-39 as a potential 
biomarker.
In tumours, elevated TGF-β levels can correlate 
with high levels of IL-4. IL-4 is a potent immuno-
modulatory cytokine secreted by T-helper 2 (Th2) 
lymphocytes, eosinophils, and mast cells. Beside 
tumours, high levels of IL-4 are present in tissues 
of patients with chronic inﬂ  ammations, in particu-
lar in atherosclerosis (Lee et al. 2006). Next we 
investigated whether IL-4 has a stimulatory effect 
on YKL-39 expression. IL-4 alone showed weak 
stimulatory effect on the YKL-39 mRNA level in 
macrophages from all ﬁ  ve donors investigated 
(lowest 1.9 times and highest 4.7 times) (Fig. 1A, 
Table 1). However the dramatic effect was observed 
if IL-4 was used in combination with TGF-β. 
Monocytes derived from four out of ﬁ  ve donors 
responded to IL-4/TGF-β combination by 9.2 to 
83.6 fold over-expression of YKL-39 mRNA 
(Fig. 1A, Table 1). Both, the effect of IL-4 alone 
and IL-4 in combination with TGF-β were 
statistically significant (p-values 0.006 and 
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Figure 1. (A) Analysis of YKL-39 mRNA expression in primary human 
monocyte-derived macrophages. YKL-39 levels were normalized to 
GAPDH mRNA expression. Five individual donors are presented. 
Normalized expression level in control sample of donor 305.1 was 
taken as a 1. Stimulations were performed for 6 days in X-vivo 
medium. B) Statistical analysis of the effects of different stimuli on 
the expression of YKL-39 in primary human monocyte derived 
macrophages. Dots represent expression levels obtained for 
individual donors. Mean values are indicated as lines. p-values were 
obtained using ANOVA.
0.05 respectively) (Fig. 1B). Thus IL-4 and TGF-β 
exhibit co-operative effect and modulate macro-
phages phenotype.
Our data suggest that monocytes recruited to 
the sites of chronic inﬂ  ammation, are typically 
characterized by concomitant presence of IL-4 and 
TGF-β, can be a source of YKL-39. This co-
operative action can be expected in case of many 
tumours, atherosclerosis and other types of chronic 
inflammation. Since chronic inflammatory 
conditions are frequently characterized by mixed 
immunological proﬁ  le of Th1 and Th2 reactions, 
we decided to analyze the effect of IFNγ, prototype 
Th1 cytokine on YKL-39 expression. IFNγ alone 
did not have modulatory effect on YKL-39 43
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expression, however it slightly inhibited the 
stimulatory effect of TGF-β (Fig. 1A, Table 1). It 
was recently demonstrated, that Th1 cells predominate 
in the synovium of patients with OA (Ishii et al. 
2002). IFNγ seems to be prevailing cytokine in OA 
tissues, and IFNγ has inhibitory effect on the 
production of YKL-39 by monocyte-derived 
macrophages. Thus synovial fibroblasts likely 
represent the major source of YKL-39 in OA.
Glucocorticoids are universally used anti-
inﬂ  ammatory therapeutics. Next, we analyzed 
whether synthetic glucocorticoid dexamethasone, 
applied at therapeutic concentrations, has an effect 
on the induction of YKL-39 by IL-4 and TGF-β. 
We found, that dexamethasone significantly 
decreased stimulatory effect both for IL-4 and 
TGF-β stimulations as well as for the combined 
stimulation for most of donors (Fig. 1A).
In summary, our data indicate, that YKL-39 
can be considered in future as a biomarker for 
speciﬁ  c macrophage activation with IL-4 and 
TGF-β, which can occur in tumours and chronic 
inﬂ  ammations, and particularly in atherosclerosis. 
Generation of speciﬁ  c anti-YKL-39 antibodies is 
an urgent next step to evaluate the amount of 
YKL-39 protein produced by macrophages as well 
as quantiﬁ  cation of YKL-39 protein in tissues and 
in circulation.
Further perspective is the evaluation of YKL-
39 both on mRNA and protein level in neurode-
generative diseases. Many evidences indicate that 
abnormal TGF-β signalling in neuronal cells 
contributes to the progression of Alzheimer 
diseases (AD). At the same time very recent data 
indicate that activation of microglia can have an 
essential role during Alzheimer disease progres-
sion. Microglia is a primary component of innate 
immune response in the brain and is associated 
with neuritic plaques in Alzheimer disease (AD). 
Type of microglial activation is currently a con-
troversial issue. Recent data indicate that microg-
lia in AD may exhibit a hybrid activation state 
that includes characteristics of classical and alter-
native activation (Colton et al. 2006). However 
the role co-operative effect of cytokines and 
TGF-β on microglia activation was not addressed. 
In the future YKL-39 can serve as a biomarker 
which indicates the direction of microglial 
polarisation.
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